XOMA Key Statistics, Chart & Performance
The current stock price of XOMA is 31.845 USD. In the past month the price decreased by -8.47%. In the past year, price decreased by -4.8%.
XOMA Latest News, Press Relases and Analysis
XOMA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.53 | 409.49B | ||
| AMGN | AMGEN INC | 15.6 | 183.64B | ||
| GILD | GILEAD SCIENCES INC | 15.52 | 157.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.76 | 110.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.49 | 83.45B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.75 | 56.34B | ||
| INSM | INSMED INC | N/A | 44.18B | ||
| NTRA | NATERA INC | N/A | 32.46B | ||
| BIIB | BIOGEN INC | 10.87 | 26.68B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.41 | 21.97B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About XOMA
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORPORATION
2200 Powell Street, Suite 310
Emeryville CALIFORNIA 94608 US
CEO: James Neal
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORPORATION / XOMA FAQ
Can you describe the business of XOMA ROYALTY CORPORATION?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Can you provide the latest stock price for XOMA ROYALTY CORPORATION?
The current stock price of XOMA is 31.845 USD. The price increased by 0.14% in the last trading session.
Does XOMA ROYALTY CORPORATION pay dividends?
XOMA does not pay a dividend.
What is the ChartMill rating of XOMA ROYALTY CORPORATION stock?
XOMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is XOMA stock listed?
XOMA stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for XOMA ROYALTY CORPORATION?
XOMA ROYALTY CORPORATION (XOMA) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORPORATION (XOMA)?
The PE ratio for XOMA ROYALTY CORPORATION (XOMA) is 42.46. This is based on the reported non-GAAP earnings per share of 0.75 and the current share price of 31.845 USD.
XOMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XOMA. When comparing the yearly performance of all stocks, XOMA is a bad performer in the overall market: 63.37% of all stocks are doing better.
XOMA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XOMA. While XOMA is still in line with the averages on profitability rating, there are concerns on its financial health.
XOMA Financial Highlights
Over the last trailing twelve months XOMA reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.93% | ||
| ROE | -19.17% | ||
| Debt/Equity | 1.11 |
XOMA Forecast & Estimates
10 analysts have analysed XOMA and the average price target is 72.08 USD. This implies a price increase of 126.35% is expected in the next year compared to the current price of 31.845.
For the next year, analysts expect an EPS growth of 126.86% and a revenue growth 85% for XOMA